Sun Pharma and Philogen enter into a exclusive commercialization and supply agreement for Fibromun

Sun Pharma will have the exclusive worldwide rights to commercialise Fibromun

Merck to acquire Harpoon Therapeutics for US$ 680 million

Acquisition includes HPN328, an investigational delta-like ligand 3 (DLL3) targeting T-cell engager being evaluated in certain patients with small cell lung cancer and neuroendocrine tumors

Vertex and CRISPR Therapeutics announce USFDA approval of Casgevy for treatment of sickle cell disease

Approximately 16,000 patients 12 years of age and older with severe sickle cell disease may now be eligible for this one-time treatment

Evonik starts construction of new U.S. facility for pharmaceutical lipids

Cooperative agreement with U.S. Government to advance U.S. biopharma industry and ensure pandemic preparedness

Evonik starts construction of US$220 million lipid innovation center in Lafayette

Cooperative agreement with U.S. Government to advance U.S. biopharma industry and ensure pandemic preparedness

Evonik opens new facility for pharmaceutical lipids in Germany

New GMP facility for clinical and small-scale commercial pharmaceutical lipids

CellOrigin Biotech collaborates with Qilu Pharma to develop CAR-iMAC Cell Therapy

Regen BioPharma develops novel dedifferentiation approach for increasing efficacy of CAR-T Cells to treat solid tumors

Company creates Younger T Cells for fighting cancer using its NR2F6 technology

Evonik to build new lipid production facility for mRNA-based therapies in U.S.

Construction will begin in early 2023, and the plant is scheduled to go onstream in 2025

CHMP recommends EU approval of Roche’s Tecentriq as adjuvant treatment

If approved, Tecentriq will be the first and only cancer immunotherapy available for certain people with early-stage NSCLC in Europe